• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial
This study is registered with ClinicalTrials.gov, number NCT01393808, and the European Union Clinical Trials Register, number 2011-001713-14. Findings Between Dec 13, 2011, and Feb 17, 2015, we randomly allocated 57 (50%) patients to a low-sodium diet (28 [49%] to paricalcitol then placebo and 29 [51%] to placebo then paricalcitol) and 58 (50%) to a high-sodium diet (29 [50%] to paricalcitol then placebo and 29 [50%] to placebo then paricalcitol). In the low-sodium group (30 mEq of daily sodium intake reduction, equivalent to approximately 1·7–1·8 g per day), 24 h albuminuria was reduced by 36·6% (95% CI 28·5–44·9...
Source: The Lancet Diabetes and Endocrinology - November 3, 2017 Category: Endocrinology Source Type: research

Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy
ConclusionsThe combined effects of ARBs on ESRD and CVD and mortality in patients with diabetic nephropathy vary considerably between patients. A substantial proportion of patients remain at high risk for both outcomes despite ARB treatment.
Source: Diabetes, Obesity and Metabolism - August 11, 2016 Category: Endocrinology Authors: N. G. C. Sande, J. A. N. Dorresteijn, F. L. J. Visseren, J. P. Dwyer, P. J. Blankestijn, Y. Graaf, H. L. J. Heerspink Tags: ORIGINAL ARTICLE Source Type: research

Individualized prediction of the effect of angiotensin receptor inhibition on renal and cardiovascular outcomes in patients with diabetic nephropathy
Conclusions The combined effects of ARBs on ESRD and CVD and mortality in patients with diabetic nephropathy varies considerably between patients. A substantial proportion of patients remain at high risk for both outcomes despite ARB treatment.
Source: Diabetes, Obesity and Metabolism - June 23, 2016 Category: Endocrinology Authors: Nicolette G.C. van der Sande, Jannick A.N. Dorresteijn, Frank. L.J. Visseren, Jamie P. Dwyer, Peter J. Blankestijn, Yolanda van der Graaf, Hiddo L. Heerspink Tags: ORIGINAL ARTICLE Source Type: research